There are a lot of quality shares for investors to choose from on the ASX 200 index.
In order to narrow things down for investors, listed below are three ASX 200 shares that are rated highly by analysts and could be quality buy and hold options.
Here's what you need to know about them:
Image source: Getty Images
Goodman Group (ASX: GMG)
The first ASX 200 share that could be a great buy and hold option is Goodman Group. It is a leading integrated commercial and industrial property group that owns a high quality portfolio of assets. Given that a good portion of its portfolio has exposure to structural tailwinds such as ecommerce and the digital economy, they look likely to be in demand with customers for a long time to come. This should be supportive of strong rental income and distribution growth over the next decade.
Citi is a fan of Goodman and has a buy rating and $24.00 price target on its shares.
Ramsay Health Care Limited (ASX: RHC)
Another ASX 200 share to consider as a buy and hold investment is Ramsay Health Care. It is a leading private healthcare company with operations across the world. After struggling during the pandemic, Ramsay has started to bounce back and looks set to benefit from a backlog in surgeries in the near term. Looking further ahead, the company appears well-placed for long term growth thanks to increasing demand for healthcare services due partly to ageing populations and increased chronic disease.
Morgans is positive on the company and has an add rating and $74.41 price target on its shares.
ResMed Inc. (ASX: RMD)
A final ASX 200 share to buy and hold could be ResMed. It is a medical device company with a focus on the sleep treatment market. Thanks to its industry-leading products, wide distribution network, and successful acquisitions, ResMed has been growing at a solid rate for years. The good news is that thanks to its significant market opportunity and the growing prevalence of sleep disorders, it has been tipped to continue this trend long into the future.
Citi is also bullish on ResMed and has a buy rating and $39.00 price target on its shares.
